Who are Mifepristone and misoprostol's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mifepristone-and-misoprostol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Mifepristone and misoprostol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mifepristone and misoprostol (Mifepristone and misoprostol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Progesterone antagonist + prostaglandin analog combination. Area: Reproductive Health / Obstetrics.

marketed Progesterone antagonist + prostaglandin analog combination Progesterone receptor (mifepristone); prostaglandin E1 receptor (misoprostol) Reproductive Health / Obstetrics Small molecule Live · refreshed every 30 min

Target snapshot

Mifepristone and misoprostol (Mifepristone and misoprostol) — Gynuity Health Projects. Mifepristone blocks progesterone receptors to stop pregnancy development, while misoprostol causes uterine contractions to expel pregnancy tissue.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mifepristone and misoprostol TARGET	Mifepristone and misoprostol	Gynuity Health Projects	marketed	Progesterone antagonist + prostaglandin analog combination	Progesterone receptor (mifepristone); prostaglandin E1 receptor (misoprostol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Progesterone antagonist + prostaglandin analog combination class)

Gynuity Health Projects · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mifepristone and misoprostol — Competitive Intelligence Brief. https://druglandscape.com/ci/mifepristone-and-misoprostol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab